Lurbinectedin for the treatment of small cell lung cancer
1Key Laboratory of Shenzhen Respiratory Diseases, Institute of Respiratory Disease, The Second Affiliated Hospital of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, China.
Abstract:
Small cell lung cancer (SCLC) is a rapidly progressive, aggressive metastatic and lethal subtype of lung cancer. Unfortunately, there has been little progress regarding the development of novel treatments for SCLC. However, lurbinectedin, a transcriptional inhibitor, has emerged as a potential novel treatment for cancer. It produces antitumor efficacy by inhibiting oncogenic transcription activity, inducing the accumulation of DNA double-strand breaks and modulating the tumor microenvironment (TME). Data from phase I/II trials indicates that lurbinectedin has significant antitumor efficacy and tolerable adverse effects in SCLC patients. Furthermore, lurbinectedin is efficacious in platinum-sensitive and platinum-resistant SCLC patients and in those with SCLC relapse after second-line treatment. In 2020, the U.S. Food and Drug Administration (FDA) approved lurbinectedin for the treatment of adult patients with metastatic SCLC or for patients that have received platinum-based chemotherapy. In this review, we discuss the molecular profile and the preclinical and clinical studies of lurbinectedin in the treatment of SCLC patients.
Insights
Lurbinectedin shows promise as a novel treatment for small cell lung cancer (SCLC). This transcriptional inhibitor demonstrates significant efficacy and tolerable side effects in SCLC patients, including those with resistant disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic advancements.
- Novel treatment strategies are urgently needed for SCLC patients.
Purpose of the Study:
- To review the molecular profile, preclinical data, and clinical studies of lurbinectedin for SCLC treatment.
- To evaluate lurbinectedin's efficacy in various SCLC patient populations.
Main Methods:
- Review of preclinical studies investigating lurbinectedin's mechanism of action.
- Analysis of Phase I/II clinical trial data in SCLC patients.
- Examination of lurbinectedin's efficacy in platinum-sensitive and platinum-resistant SCLC.
Main Results:
- Lurbinectedin exhibits antitumor efficacy by inhibiting transcription, inducing DNA breaks, and modulating the tumor microenvironment.
- Phase I/II trials show significant efficacy and tolerable adverse effects in SCLC patients.
- Lurbinectedin is effective in platinum-sensitive, platinum-resistant, and relapsed SCLC.
Conclusions:
- Lurbinectedin is a promising novel therapeutic agent for SCLC.
- FDA approval in 2020 supports its use in metastatic SCLC and post-chemotherapy relapse.
- Further understanding of its molecular profile and clinical data supports its role in SCLC treatment.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
